Literature DB >> 3135102

Effects of a one-year administration of phosphate and intermittent calcitonin on bone-forming and bone-resorbing cells in involutional osteoporosis: a histomorphometric study.

C Alexandre1, D Chappard, F Caulin, A Bertrand, S Palle, G Riffat.   

Abstract

The bone histomorphometric effects of intermittent phosphate and calcitonin therapy during 1 year were analyzed in 15 involutional osteoporotic patients. Phosphate was administered continuously (1.5 g/day) and calcitonin was injected during 5 days every third week (50 IU/day). The bone cell response was analyzed in two separate groups, according to the amount of trabecular bone present in the iliac bone biopsy: patients with trabecular bone volume (TBV) beyond the histomorphometric spontaneous fracture threshold (0.16 mm3/mm3) (group 1; 11 patients) and patients with TBV above this threshold (group 2; 4 patients). In group 1, the treatment significantly increased TBV from 0.113 +/- 0.025 to 0.156 +/- 0.046 mm3/mm3 by thickening the existing trabeculae rather than by creating new trabeculae; stimulation of bone formation rate (+ 50%) and significant reduction in active trabecular resorption surfaces (from 0.021 +/- 0.013 to 0.010 +/- 0.006 mm2/mm2; P less than .05) may have led to positive bone balance. In group 2, TBV was not changed because of the treatment's relative inefficiency for reducing the bone-resorbing cell activity, leading to likely persistent negative bone balance. Cortical thickness did not change in either group. This study confirms the positive effectiveness of continuous treatment with phosphate and intermittent calcitonin during 1 year on bone balance in involutional osteoporosis with low amount of bone. The lack of response in patients with normal amount of bone must be verified before raising the hypothesis of different bone cell activity and before anticipating the therapeutic response according to local bone mass besides bone remodeling status in osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135102     DOI: 10.1007/bf02556351

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  22 in total

Review 1.  Treatment of osteoporoses by manipulation of coherent bone cell populations.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1979-09       Impact factor: 4.176

Review 2.  The pathomechanics of osteoporoses.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1985-11       Impact factor: 4.176

3.  Embedding iliac bone biopsies at low temperature using glycol and methyl methacrylates.

Authors:  D Chappard; C Alexandre; M Camps; J P Montheard; G Riffat
Journal:  Stain Technol       Date:  1983-09

4.  Long-term calcitonin therapy in postmenopausal osteoporosis.

Authors:  H E Gruber; J L Ivey; D J Baylink; M Matthews; W B Nelp; K Sisom; C H Chesnut
Journal:  Metabolism       Date:  1984-04       Impact factor: 8.694

5.  Treatment of osteoporosis with fluoride, calcium, and vitamin D.

Authors:  D Briancon; P J Meunier
Journal:  Orthop Clin North Am       Date:  1981-07       Impact factor: 2.472

6.  Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.

Authors:  J F Aloia; A Vaswani; P J Meunier; C M Edouard; M E Arlot; J K Yeh; S H Cohn
Journal:  Calcif Tissue Int       Date:  1987-05       Impact factor: 4.333

7.  Stimulation of bone formation in vivo by phosphate supplementation.

Authors:  W H Harris; R P Heaney; L A Davis; E H Weinberg; R D Coutts; A L Schiller
Journal:  Calcif Tissue Res       Date:  1976-11-24

8.  Effects of phosphorus supplementation on serum parathyroid hormone and bone morphology in osteoporosis.

Authors:  R S Goldsmith; J Jowsey; W J Dubé; B L Riggs; C D Arnaud; P J Kelly
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

9.  [Histomorphometry. Method for evaluating the bone mass].

Authors:  P J Meunier; P Chavassieux
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-12

10.  Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of Iliac crest bone from untreated patients.

Authors:  M P Whyte; M A Bergfeld; W A Murphy; L V Avioli; S L Teitelbaum
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

View more
  4 in total

1.  Effects of a short course of oral phosphate treatment on serum parathyroid hormone(1-84) and biochemical markers of bone turnover: a dose-response study.

Authors:  K Brixen; H K Nielsen; P Charles; L Mosekilde
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

Review 2.  Osteoporosis prevention and therapy: preserving and building strength through bone quality.

Authors:  M Kleerekoper
Journal:  Osteoporos Int       Date:  2006-08-15       Impact factor: 4.507

Review 3.  [Calcitonin and osteoporosis--a critical review of the literature 1980-1989].

Authors:  H G Haas; B M Liebrich; W Schaffner
Journal:  Klin Wochenschr       Date:  1990-04-02

4.  Dapagliflozin Attenuates Hyperglycemia Related Osteoporosis in ZDF Rats by Alleviating Hypercalciuria.

Authors:  Ji-Yu Wang; Yan-Zhen Cheng; Shuang-Li Yang; Min An; Hua Zhang; Hong Chen; Li Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-05       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.